Company Overview
Snapshot
Founded in July 2017 by Guy Neev and Marius Nacht, Aummune operates with 1-10 employees. The company has secured funding across one round from one investor, aMoon Fund. Aummune is currently recruiting patients for its First-in-Human Phase 1 clinical trial for its lead program, AM003, targeting locally advanced and metastatic solid tumors.
Business overview
Aummune is a clinical-stage company specializing in Health Tech & Life Sciences, particularly in Pharma & Medical Biotechnology. The company develops a novel approach for individualized treatment of solid tumors, utilizing a proprietary platform that employs an efficacy-driven selection process to create patient-specific tri-functional oligonucleotide drugs. These drugs are designed to induce cancer cell death and activate both innate and adaptive immune responses. Aummune's core technology involves Biologicals, specifically Molecules, targeting the Pharmaceuticals segment within the broader Healthcare & Life Sciences market globally.
Log in to access full profile ›Company Intelligence Q&A
- What is Aummune's primary focus in the healthcare sector?
- Aummune is focused on developing individualized immunotherapy treatments for solid tumors, leveraging a proprietary platform to create patient-specific tri-functional oligonucleotide drugs.
- When was Aummune founded and by whom?
- Aummune was founded in July 2017 by Guy Neev and Marius Nacht.
- What is the current development stage of Aummune's lead program?
- Aummune's lead program, AM003, has initiated its Phase 1 clinical trial and is actively recruiting patients for this First-in-Human study, targeting locally advanced and metastatic solid tumors.
- What is the mechanism of action for Aummune's proprietary drug platform?
- Aummune's platform utilizes a unique efficacy-driven selection process to produce a patient-specific tri-functional oligonucleotide drug designed to safely and synergistically induce cancer cell death and activate both innate and adaptive immune responses.